Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
Status:
Completed
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
To determine the hearing response rate at 24 weeks after treatment with bevacizumab for
symptomatic vestibular schwannomas (VS) in children and young adults with Neurofibromatosis
Type 2 (NF 2).